Supplementary materials: Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

These are peer-reviewed supplementary materials for the article 'Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma' published in the Journal of Comparative Effectiveness Research.Data sources, study designs, and analysis methodsPatients treated with teclistamab in MajesTEC-1Flatiron Health databaseAnalysis populations and designAim: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59–1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p < 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.

本数据集为发表于《比较疗效研究杂志》的论文《Teclistamab与真实世界医师选择的疗法在多发性骨髓瘤三线治疗失败/复发患者中的比较》的同行评审补充材料。数据来源、研究设计和分析方法：MajesTEC-1数据库中接受teclistamab治疗的患者的数据分析。研究对象和设计：研究旨在比较teclistamab与真实世界医师选择的疗法（RWPC）在多发性骨髓瘤三线治疗失败/复发患者中的疗效。研究方法：对RWPC队列应用MajesTEC-1的纳入标准。通过逆概率治疗加权法调整基线协变量不平衡。比较总生存期、无进展生存期和至下一次治疗时间。研究结果：经过逆概率治疗加权后，两组队列（teclistamab组，n = 165；RWPC组，n = 364 [766个观察值]）的基线特征相似。接受teclistamab治疗的患者在总生存期（风险比 [HR]: 0.82 [95% CI: 0.59–1.14]; p = 0.233）方面显示出数值上的改善，且与RWPC队列相比，显著提高了无进展生存期（HR: 0.43 [0.33–0.56]; p < 0.0001）和至下一次治疗时间（HR: 0.36 [0.27–0.49]; p < 0.0001）。结论：在多发性骨髓瘤三线治疗失败/复发患者中，Teclistamab相较于RWPC提供了临床上的益处。